Compare BELFA & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFA | FTRE |
|---|---|---|
| Founded | 1949 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.5B |
| IPO Year | N/A | N/A |
| Metric | BELFA | FTRE |
|---|---|---|
| Price | $182.25 | $17.36 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | 54.9K | ★ 1.2M |
| Earning Date | 02-17-2026 | 03-02-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ 19.52 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | $649,376,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $28.52 | $3.17 |
| Revenue Next Year | $6.49 | $0.07 |
| P/E Ratio | $35.93 | ★ N/A |
| Revenue Growth | ★ 23.70 | 1.88 |
| 52 Week Low | $53.95 | $3.97 |
| 52 Week High | $189.32 | $19.00 |
| Indicator | BELFA | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 71.01 | 57.07 |
| Support Level | $155.74 | $15.37 |
| Resistance Level | $187.73 | $17.24 |
| Average True Range (ATR) | 7.44 | 1.20 |
| MACD | 1.54 | -0.23 |
| Stochastic Oscillator | 85.26 | 61.21 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.